The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PBYI | +84.15% | -44.95% | -11.25% | -61% |
| S&P | +14.5% | +93.32% | +14.09% | +386% |
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
The company's CEO bought $2.5 million worth of company stock.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $52.44M | 11.4% |
| Gross Profit | $40.14M | 10.2% |
| Gross Margin | 76.54% | -0.8% |
| Market Cap | $170.26M | 8.3% |
| Market Cap / Employee | $0.99M | 0.0% |
| Employees | 172 | -7.0% |
| Net Income | $5.86M | 229.3% |
| EBITDA | $9.40M | 1189.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $56.75M | -15.5% |
| Accounts Receivable | $25.91M | -7.8% |
| Inventory | 8.6 | -5.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $10.87M | -77.4% |
| Short Term Debt | $38.36M | -24.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 24.23% | 19.9% |
| Return On Invested Capital | -8.88% | 16.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $14.06M | 1296.4% |
| Operating Free Cash Flow | $14.08M | 1271.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 5.37 | 5.00 | 3.85 | 3.50 | -80.37% |
| Price to Book | 1.76 | 2.11 | 1.58 | 1.75 | -43.16% |
| Price to Sales | 0.51 | 0.65 | 0.63 | 0.72 | 0.57% |
| Price to Tangible Book Value | 7.14 | 8.54 | 3.55 | 3.52 | -116.67% |
| Price to Free Cash Flow TTM | 3.72 | 3.88 | 4.74 | 3.89 | -17.85% |
| Enterprise Value to EBITDA | 4.61 | 7.64 | 17.15 | 13.10 | -94.00% |
| Free Cash Flow Yield | 26.9% | 25.8% | 21.1% | 25.7% | 21.73% |
| Return on Equity | 42.3% | 41.6% | 51.4% | 63.2% | 186.14% |
| Total Debt | $86.37M | $74.08M | $61.71M | $49.23M | -50.06% |
PBYI earnings call for the period ending September 30, 2020.
PBYI earnings call for the period ending June 30, 2020.
PBYI earnings call for the period ending March 31, 2020.
PBYI earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
